As the existing comprehensive recommendations for cancer control policies are mostly derived from Western countries, non-Western nations should strive to tailor their own policies based on their local lifestyle, burden of cancer and characteristics of the local healthcare system.
Newer molecular tests for high-risk human papillomavirus (hrHPV) may provide a cost-effective means for cervical cancer screening for low-to-middle income countries (LMICs), with results comparable to cervical biopsies.
The Union for International Cancer Control (UICC) invites cities in Asian countries to participate in the global initiative of City Cancer Challenge (CCC) and upgrade their healthcare services for cancer patients.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.
Pembrolizumab monotherapy improves overall
survival (OS) and cancer control compared with platinum-based chemotherapy in
patients with untreated locally advanced or metastatic programmed death-ligand
1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11
or KEAP1 mutation status, according to results of the phase III